1st Cardiology Clinic, "Hippokration" General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
3rd Department of Internal Medicine, "Papageorgiou Hospital", Aristotle University of Thessaloniki, Thessaloníki, Greece.
Clin Drug Investig. 2019 Apr;39(4):385-393. doi: 10.1007/s40261-019-00761-0.
Despite the overwhelming evidence and the established benefits of antihypertensive treatment, adherence to treatment remains low.
To assess the adherence to treatment with a perindopril/indapamide/amlodipine single-pill combination (SPC), its effectiveness on blood pressure (BP) reduction, as well as the safety and tolerability of this SPC over a 4-month treatment period.
This multicenter, non-interventional study prospectively included 2285 hypertensive patients on perindopril/indapamide/amlodipine SPC. The data were recorded at baseline, 1 month, and 4 months.
Of the 2285 hypertensive patients included in the study, 50.5% were at "high/very high risk". Mean systolic (SBP)/diastolic (DBP) decreased from 162.3 ± 13.3/93.1 ± 9.3 mmHg at baseline to 129.7 ± 8.3/78.6 ± 7.1 mmHg at 4 months (p < 0.001). Patients with higher baseline BP levels showed greater BP reduction. Patients with hypertension stages 1, 2, and 3 showed mean SBP/DBP reductions of 21.5/10.4 mmHg, 34.2/14.7 mmHg, and 51.2/22.5 mmHg, respectively, at study end (p < 0.001). Only 26 patients (1.1%) prematurely discontinued treatment (0.58% due to an adverse reaction or event).
Perindopril/indapamide/amlodipine SPC decreased BP levels rapidly and significantly. The degree of BP reduction was associated with the severity of hypertension and/or with total cardiovascular risk at baseline. Simplifying the drug regimen by using this SPC improved adherence and showed excellent tolerability.
尽管有压倒性的证据和已确立的降压治疗益处，但治疗的依从性仍然很低。
评估培哚普利/吲达帕胺/氨氯地平单片复方制剂（SPC）的治疗依从性、其降低血压的效果，以及在 4 个月治疗期间该 SPC 的安全性和耐受性。
这项多中心、非干预性研究前瞻性纳入了 2285 例接受培哚普利/吲达帕胺/氨氯地平 SPC 的高血压患者。数据在基线、1 个月和 4 个月时记录。
在这项研究中，2285 例高血压患者中，50.5%处于“高/极高风险”。收缩压（SBP）/舒张压（DBP）从基线时的 162.3±13.3/93.1±9.3mmHg 降至 4 个月时的 129.7±8.3/78.6±7.1mmHg（p<0.001）。基线血压水平较高的患者血压下降幅度更大。高血压 1 期、2 期和 3 期的患者在研究结束时的 SBP/DBP 平均降幅分别为 21.5/10.4mmHg、34.2/14.7mmHg 和 51.2/22.5mmHg（p<0.001）。只有 26 例患者（1.1%）提前停药（0.58%因不良反应或事件）。
培哚普利/吲达帕胺/氨氯地平 SPC 可迅速显著降低血压水平。降压幅度与高血压严重程度和/或基线时的总心血管风险相关。通过使用这种 SPC 简化药物治疗方案可提高依从性，并表现出极好的耐受性。
